Neurological & CognitiveIntl. Approved (Russia)S

Selank

Tuftsin Analog TP-7

Selank is a synthetic heptapeptide anxiolytic based on the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), developed and approved in Russia for generalized anxiety disorder and as an immunomodulator. It demonstrates anxiolytic and nootropic effects comparable to benzodiazepines but without the sedation, dependence potential, or memory impairment. Administered intranasally. Not FDA-approved in the US.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
5
Research grade
S
Community score
174

Trend index

Trackers
3,068

Overview

About Selank

Selank is a synthetic heptapeptide anxiolytic based on the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), developed and approved in Russia for generalized anxiety disorder and as an immunomodulator. It demonstrates anxiolytic and nootropic effects comparable to benzodiazepines but without the sedation, dependence potential, or memory impairment. Administered intranasally. Not FDA-approved in the US.

Category
Neurological & Cognitive
Regulatory status
Intl. Approved (Russia)
Also known as
Tuftsin Analog TP-7
Self-reports
57

Community

What 57 users report

57 community reports

Positive 3% · Neutral 97% · Negative 0%

Most reported benefits

Mood
184
Recovery
184

Most reported side effects

Injection site irritation
94
Fatigue
85

Dose distribution

Median: 200–400 mcg · Most common: 200–400 mcg

0–25
0
25–50
0
50–100
0
100–200
3
200–400
96
400–600
76
600–1000
5
1000–2000
2
2000+
2

How repeat users are trending

Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 54 days · Based on 35 repeat reporters

Research

Cited research (3)

Help

Frequently asked

What do PeptIQ users report about Selank?

This page summarizes 57 anonymized self-reports from PeptIQ users who track Selank, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Selank?

3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Selank safe to use?

This wiki does not assess safety or recommend use. Selank is listed as Intl. Approved (Russia). Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Selank?

Research, primarily in animal models, suggests Selank may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Selank?

Selank is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Selank as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Selank?

The safety and effectiveness of Selank have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Selank?

While there are over 200 published studies on Selank, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source